Nitric oxide and atherosclerosis: an update.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms and clinical concepts without systematic search methodology.
PubMed 16684613 · doi:10.1016/j.niox.2006.03.011
What was done
This is a narrative review summarizing the physiological roles and mechanisms of nitric oxide (NO) in vascular disease and atherosclerosis. The authors outline the cellular actions of NO, endothelial nitric oxide synthase (eNOS) bioactivity, the impact of reactive oxygen species, the therapeutic potential of L-arginine, and eNOS gene polymorphisms.
What was found
The abstract reports no quantitative data or numerical outcomes. It describes qualitatively that NO promotes vasorelaxation and endothelial regeneration while inhibiting leukocyte chemotaxis and platelet adhesion. Atherosclerosis reduces eNOS bioactivity and accelerates NO degradation through reactive oxygen species, whereas L-arginine and other vasculoprotective agents operate through NO pathways.
Why it matters
It synthesizes the mechanistic links between endothelial dysfunction, oxidative stress, and impaired nitric oxide signaling in cardiovascular disease. This framework helps contextualize potential therapeutic targets for vascular protection.
Limits
The abstract contains no primary human data, quantitative effect sizes, sample sizes, or systematic study selection criteria. The clinical utility of L-arginine and the prognostic role of eNOS polymorphisms remain inconclusive and require further clinical investigation.
Cited by
- supports Shear stress on arterial endothelium increases nitric oxide production, which dilates blood vessels, prevents platelet clumping, and reduces cholesterol plaque formation.